| Primary |
| Hepatitis B |
60.3% |
| Diabetes Mellitus |
6.9% |
| Cerebrovascular Accident Prophylaxis |
3.4% |
| Hepatic Failure |
3.4% |
| Hypertension |
3.4% |
| Hiv Infection |
2.9% |
| Chronic Hepatitis B |
2.6% |
| Hepatitis B Virus Test |
2.3% |
| Psoriatic Arthropathy |
2.3% |
| Diarrhoea |
1.7% |
| Sinusitis |
1.4% |
| Antiviral Treatment |
1.1% |
| Hepatic Cirrhosis |
1.1% |
| Hepatitis B Virus |
1.1% |
| Insomnia |
1.1% |
| Rhinitis Allergic |
1.1% |
| Cardiovascular Disorder |
0.9% |
| Hepatitis D |
0.9% |
| Nasopharyngitis |
0.9% |
| Prophylaxis |
0.9% |
|
| Drug Resistance |
15.9% |
| Lactic Acidosis |
12.8% |
| Hepatic Neoplasm Malignant |
10.4% |
| Hepatic Failure |
7.9% |
| Pancreatitis |
5.5% |
| Blood Bilirubin Increased |
4.3% |
| Blood Hiv Rna Decreased |
4.3% |
| Vomiting |
4.3% |
| Squamous Cell Carcinoma |
3.7% |
| Hepatic Encephalopathy |
3.0% |
| Listeria Encephalitis |
3.0% |
| Pancreatitis Acute |
3.0% |
| Pregnancy |
3.0% |
| Renal Failure |
3.0% |
| Renal Impairment |
3.0% |
| Transaminases Increased |
3.0% |
| Ascites |
2.4% |
| Hbv Dna Increased |
2.4% |
| Lung Adenocarcinoma |
2.4% |
| Prothrombin Time Prolonged |
2.4% |
|
| Secondary |
| Hepatitis B |
43.5% |
| Drug Use For Unknown Indication |
9.1% |
| Hiv Infection |
6.9% |
| B-cell Lymphoma |
6.0% |
| Infection Prophylaxis |
3.9% |
| Antiretroviral Therapy |
3.6% |
| Gastroenteritis |
3.6% |
| Hepatic Failure |
3.6% |
| Chronic Hepatitis B |
3.0% |
| Chronic Lymphocytic Leukaemia |
1.8% |
| Gastritis |
1.8% |
| Helicobacter Infection |
1.8% |
| Hepatitis Fulminant |
1.8% |
| Product Used For Unknown Indication |
1.8% |
| Splenic Marginal Zone Lymphoma |
1.5% |
| Glaucoma |
1.2% |
| Hepatitis B Virus |
1.2% |
| Hyperlipidaemia |
1.2% |
| Type 2 Diabetes Mellitus |
1.2% |
| Ventricular Tachyarrhythmia |
1.2% |
|
| Hepatitis B |
11.0% |
| Hyperlipidaemia |
9.6% |
| Viral Load Increased |
8.2% |
| Drug Ineffective |
6.8% |
| Liver Injury |
6.8% |
| Hepatic Neoplasm Malignant |
5.5% |
| Lactic Acidosis |
5.5% |
| Prothrombin Time Prolonged |
5.5% |
| Abortion Spontaneous |
4.1% |
| Drug Exposure During Pregnancy |
4.1% |
| Hepatic Encephalopathy |
4.1% |
| Therapeutic Response Decreased |
4.1% |
| Viral Myocarditis |
4.1% |
| Wrist Fracture |
4.1% |
| Agranulocytosis |
2.7% |
| Blood Bicarbonate Decreased |
2.7% |
| Fatigue |
2.7% |
| Hepatic Failure |
2.7% |
| Nocardiosis |
2.7% |
| Pancreatitis |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.2% |
| Hepatitis B |
16.1% |
| Prophylaxis |
15.5% |
| Drug Use For Unknown Indication |
8.4% |
| Aplastic Anaemia |
8.0% |
| Hepatic Neoplasm Malignant |
6.0% |
| Hiv Infection |
4.3% |
| Premedication |
3.5% |
| Infection Prophylaxis |
2.6% |
| Hypertension |
2.6% |
| Diabetes Mellitus |
2.1% |
| Chronic Myeloid Leukaemia |
2.0% |
| Multiple Myeloma |
2.0% |
| Antiviral Prophylaxis |
1.9% |
| Hepatic Cirrhosis |
1.8% |
| Hodgkin's Disease |
1.8% |
| Insomnia |
1.6% |
| Chronic Hepatitis B |
1.4% |
| Bone Marrow Conditioning Regimen |
1.1% |
| Mantle Cell Lymphoma |
1.1% |
|
| White Blood Cell Count Decreased |
10.5% |
| Hepatitis B |
7.0% |
| Pain In Extremity |
7.0% |
| Sepsis |
7.0% |
| Vomiting |
6.4% |
| Hepatic Failure |
5.8% |
| Therapeutic Response Decreased |
5.8% |
| Viral Load Increased |
5.2% |
| Pyrexia |
4.7% |
| White Blood Cell Count Increased |
4.7% |
| Hepatic Neoplasm Malignant |
4.1% |
| Pneumatosis Intestinalis |
4.1% |
| Pneumonia |
4.1% |
| Weight Decreased |
4.1% |
| Bone Marrow Failure |
3.5% |
| Febrile Neutropenia |
3.5% |
| Haemolytic Anaemia |
3.5% |
| Neutropenia |
3.5% |
| Hepatic Function Abnormal |
2.9% |
| Platelet Count Decreased |
2.9% |
|
| Interacting |
| Chronic Myeloid Leukaemia |
100.0% |
|
|
